Fosun Pharmaceuticals announced that its holding subsidiary Shanghai Fuhong Hanlin and its holding subsidiary, the registration application for HLX14 120mg/bottle, a desulfan biosimilar drug independently developed by its holding subsidiary, was recently accepted by the State Drug Administration. The declared indications are all indications that the reference drug Angarvir has been approved for marketing in China. As of August 2026, the Group's total R&D investment for HLX14 was approximately 352 million yuan.

Fosun Pharmaceuticals announced that its holding subsidiary Shanghai Fuhong Hanlin and its holding subsidiary, the registration application for HLX14 120mg/bottle, a desulfan biosimilar drug independently developed by its holding subsidiary, was recently accepted by the State Drug Administration. The declared indications are all indications that the reference drug Angarvir has been approved for marketing in China. As of August 2026, the Group's total R&D investment for HLX14 was approximately 352 million yuan.